• Profile
Close

Effect of voluntary licences for hepatitis C medicines on access to treatment: A difference-in-differences analysis

The Lancet Global Health Aug 15, 2019

Simmons B, et al. - Via a difference-in-differences analysis, researchers assessed the impact of voluntary licenses on access to hepatitis C virus (HCV) treatment. Thirty-five countries were involved in the panel, with 19 in the intervention group and 16 in the control group. Voluntary licenses were correlated with an improvement in the annual number of people accessing HCV treatment of 69.3 per 1,000 diagnosed in the simplest model, adjusting only for country and year fixed impacts. This increase was 53.6 per 1,000 diagnosed following adjustment for country-level covariates. The influence of licensing progressed over time and was biggest in the second year following implementation. Voluntary licensing initiatives seemed to substantially enhance HCV treatment uptake in qualified countries. This evidence supports expanding licensing approaches to involve more countries and more treatments.

Full text available Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay